MedTrace Logo

Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)

NCT00552240 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2014-01-27

Study results available
· View outcomes & findings →

Summary

The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).

Conditions

  • HIV Infections

Interventions

DRUG

tenofovir DF 300 mg QD

300 mg QD

DRUG

tenofovir DF 300 mg QD

300 mg QD

DRUG

emtricitabine 200 mg QD

200 mg QD

DRUG

emtricitabine 200 mg QD

200 mg QD

DRUG

Nevirapine 200 mg BID

200 mg BID

DRUG

Atazanavir 300 mg

300 mg QD

DRUG

Ritonavir 100 mg

100 mg QD

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00552240 on ClinicalTrials.gov